2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Rami Komrokji, MD, discusses the importance of establishing a clinical consensus to standardize the use of molecular testing in myelodysplastic syndromes.
Rami Komrokji, MD, vice chair, Malignant Hematology Department, Moffitt Cancer Center, discusses the role of molecular testing in myelodysplastic syndromes (MDS) and the importance of establishing a clinical consensus to standardize its use in routine practice. These considerations were highlighted in a discussion at the Bridging The Gaps: Leukemia, Lymphoma, and Multiple Myeloma in Miami, Florida.